Antares Pharma (ATRS) Stock Price
Antares Pharma Price
Over the last 19 years Antares Pharma grew revenue by 22.3% annually, reaching 183.98 M USD. For Antares Pharma, the net margin of 25.2% is up versus -30.7% a few years ago.
Antares Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Antares Pharma business model & stock analysis
Frequently asked questions about Antares Pharma
Antares Pharma Inc is a pharmaceutical company that specializes in developing and commercializing self-injection drug delivery systems. Their business model focuses on developing innovative technologies that improve the convenience, safety, and efficacy of medication administration. Antares Pharma Inc partners with pharmaceutical companies to enhance their existing products or develop new drug formulations. By providing a range of self-injection systems such as autoinjectors and pen injectors, Antares Pharma Inc aims to improve patient adherence to medication regimens and enhance the overall treatment experience. They prioritize patient-centric solutions to meet the evolving needs of the pharmaceutical industry.
Antares Pharma Inc is primarily active in the pharmaceutical industry.
The main competitors of Antares Pharma Inc in the market are pharmaceutical companies such as Eli Lilly and Company, Novartis AG, Pfizer Inc, Johnson & Johnson, and Amgen Inc.
Antares Pharma Inc. is a biopharmaceutical company specializing in the development and commercialization of self-administered parenteral pharmaceutical products. Founded in 1979, Antares Pharma has a rich history of innovation and scientific expertise. The company focuses on advanced drug delivery technologies, including its proprietary needle-free injection system, to improve patient convenience and adherence. With a strong commitment to research and development, Antares Pharma has successfully brought several products to market and licenses its technologies to pharmaceutical partners worldwide. The company's dedication to improving therapeutic outcomes has earned it a reputable position in the pharmaceutical industry.
Antares Pharma Inc has achieved significant milestones throughout its years of operation. Notably, the company received FDA approval for its flagship product, the Otrexup™ self-injection device, a breakthrough treatment for patients with rheumatoid arthritis and psoriasis. Antares also secured licensing agreements with leading pharmaceutical companies, including Teva and AMAG, further extending its market reach. In addition, the company successfully launched the Makena® subcutaneous auto injector, enhancing patient convenience for a hormone therapy drug used in high-risk pregnancies. Antares Pharma Inc continues to innovate, pursue strategic collaborations, and make remarkable progress in delivering advanced pharmaceutical solutions.
Antares Pharma Inc is primarily present in the United States.
Antares Pharma Inc represents a set of key values and a strong corporate philosophy. With a focus on innovation, Antares Pharma Inc strives to develop and commercialize pharmaceutical products that improve patients' lives. The company places great importance on quality, aiming to deliver safe and effective treatments. Antares Pharma Inc is committed to fostering a culture of integrity and ethical business practices, ensuring transparency and accountability in all its operations. By prioritizing customer needs and collaboration, Antares Pharma Inc aims to drive shareholder value and establish itself as a leader in the pharmaceutical industry.
12 analysts currently rate the Antares Pharma stock: 6 recommend buying, 6 holding and 0 selling.
The Antares Pharma share (ATRS) is listed on 2 stock exchanges, including: NASDAQ (ATRS), SIX (Zürich) (MJC.SW).
Antares Pharma Inc is a company that specializes in the development, manufacturing, and marketing of medications, particularly injection solutions. The company has three main business areas: 1. Marketing and manufacturing of medications: Antares Pharma produces and markets primarily injection solutions for various applications. The company has several leading products, including the legal opioid Vergentanib, hormone injections for women, disposable insulin pens, and more. 2. Research and development: Antares Pharma is dedicated to advancing the development of new medications and injection systems. The company heavily invests in research and development to create innovative products that meet the needs of patients. 3. Licensing and partnerships: Antares Pharma also collaborates with other pharmaceutical companies to distribute its products worldwide. The company has partnerships with companies such as Teva, Ferring, and Pfizer to globally market its products. The company offers several leading products: 1. Vergentanib: Vergentanib is a legal opioid for pain relief. The medication is administered through a pre-filled syringe pen manufactured by Antares Pharma. Vergentanib is a widely approved medication available in many countries worldwide. 2. OTREXUP: OTREXUP is a disposable insulin pen for the treatment of diabetes. The insulin pen is made from a special material that reduces the risk of overdosing. 3. QuickShot: QuickShot is a disposable injection system for hormone injections for women. The system is convenient and easy to use, and is utilized by many women around the world. Antares Pharma's business model is based on the development and marketing of injection products for various applications. The company invests in research and development to create innovative products that meet the needs of patients. Antares Pharma also collaborates with partners to market its products worldwide. The company has a strong presence in the market and strives to continue developing and distributing top-quality products to assist patients.
The revenue cannot currently be calculated for Antares Pharma.
The profit cannot currently be calculated for Antares Pharma.
The P/E ratio cannot be calculated for Antares Pharma at the moment.
The P/S cannot be calculated for Antares Pharma currently.
The Eulerpool Quality Score for Antares Pharma is 8/10.
The ISIN of Antares Pharma is US0366421065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Antares Pharma is 903128. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Antares Pharma is ATRS. The ticker symbol is used to trade Antares Pharma shares on the stock exchange.
Antares Pharma stock
Antares Pharma Peer Group
Antares Pharma Ticker
Antares Pharma FIGI
All fundamentals and in-depth analysis of Antares Pharma
Our stock analysis for Antares Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antares Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.